Team:UB Indonesia/backup

From 2014.igem.org

(Difference between revisions)
 
(22 intermediate revisions not shown)
Line 114: Line 114:
<a href="#overview" class="fancybox"><p><i class="icon icon-eye-open"></i></p></a>
<a href="#overview" class="fancybox"><p><i class="icon icon-eye-open"></i></p></a>
                                         <div id="overview" style="display:none;width:700px;">
                                         <div id="overview" style="display:none;width:700px;">
-
<h2><center>“”</center></h2>
+
<h2><center>“UB_INDONESIA BRINGS C3P (CERVICAL CANCER PROGRAM)”</center></h2>
-
<p align="justify"></p>
+
<p align="justify">
 +
Cervical cancer is the second most common cancer in women worldwide. Yet, because of poor access to screening and treatment services, the number of deaths occur in women increase highly, especially in our country, Indonesia. Effective methods for early detection of precancerous lesions using cytology (Pap smear) exist, but not effective enough for detection in all age. However, new technological developments, using synthetic biology, offer the potential to tackle cervical cancer in a more comprehensive way and build a healthier future for girls and women. Here we go with our great idea!<br><br>
 +
UB IGEM TEAM is on progress in developing C3P (Cervical Cancer Care Program) as the theme to give solutions for cervical cancer cases. Starting from creating a rapid test tool using HPV DNA which is integrated with the software, creating a high antioxidant tea for preventing efforts, and creating a kit for selecting potential anti-cancer herbs.<br><br>
 +
We try to make an idea to build a new prototype for early detection to cervical cancer, especially caused by HPV 18 and HPV 16. We construct a new specific TALEs that can bind to our target sequences and we called it TALE 1 and TALE 2. In order to make sure the presence of DNA  from HPV 16 and 18, we need reporter which connect to detector.  Fluorescent protein usually used as reporter gene to study about gene expression. It will be connected to detector using linker. When the HPV DNA is bind to detector, blue colour will appear in the second strip. The Intensity of colour will be detected in our software and we can determined the risk level of cervical cancer disease. Dark blue colour show that the amount of  DNA  from HPV 16 and 18 is high and indicate the patient get severe cervical cancer.<br><br>
 +
Beside that, we try to take the advantage of tea plant. Tea plant (Camelia sinensis) has catechin compounds that contains antioxidants.  Catechin family that most effective used as antioxidant is Epigallocathecin gallate (EGCG).  Based on research in vitro or in silico, EGCG is able to inhibit the proliferation of cancer cells because stop over-expression between L1 HPV 16- EGFR (Epithel Growth Factor Receptor) bond but there are few of EGCG content in tea plant. Based on these problems, we would to over- expression EGCG by knockdown non-compound EGCG gene, so hopefully the content of EGCG on tea are more prominent.<br><br>
 +
SCT (screening Cancer Therapy) is a kit which contains of hela cells as cervical cancer cells and it was designed to screening the plants that have compund potentially for cervical cancer therapy. Herbs that potentially as a therapy of cervical cancer in the kit are marked by the absence of green or red colors, while the negative results are marked by the emergence of green or red in the kit. The kit is expected to provide convenience to the researchers in the field of cervical cancer and cervical cancer effects can be mitigated with natural compound that not a lot of side effects. <br><br>
 +
From all of above, we bring C3P (Cervical Cancer Program) for iGEM 2014. We named our each project with preventing, screening and therapy. beside, we also do social action in other to socialize our project and be closer to society to inform them how to avoid cervical cancer. <br><br>
 +
The responsible of the scientist is not only the result in the lab, but also share “the right thing” for society. So, thanks to iGEM that gives us an opportunity for doing both, research and social action. <br><br>
 +
<b>“Share your knowledge. It’s a way to achieve immortality.” - Dalai Lama</b>
 +
</p>
                                         </div>
                                         </div>
<h2 class="font-thin"><font color="#fff">Overview</font></h2>
<h2 class="font-thin"><font color="#fff">Overview</font></h2>
Line 123: Line 132:
                                         <div id="preventing" style="display:none;width:700px;">
                                         <div id="preventing" style="display:none;width:700px;">
<h2><center>“Prevent is Better than Cure”</center></h2>
<h2><center>“Prevent is Better than Cure”</center></h2>
-
<p align="justify">Indonesia is an agricultural country that most of their society works as farmer. One of commodity in Indonesia is tea plantation which is located in Malang (Brawijaya University takes place). Malang is resited at 440-667 (mdpl) altitude, one of the tourist destinations in East Java because of the potential of natural and climatic owned. Malang climate conditions during 2008 temperatures recorded ranging from 22.7 ° C to 25.1 ° C. While the maximum temperature reached 32.7 ° C and minimum temperature of 18.4 ° C. The average air humidity range 79% - 86%. With a maximum moisture content of 99% and a minimum at 40%. These conditions favor the development of the tea plant (Camellia sinensis). <br><br>
+
<p align="justify">Indonesia is an agricultural country that most of their society works as farmer. One of commodity in Indonesia is tea plantation which is located in Malang (Brawijaya University takes place). Malang is resited at 440-667 (mdpl) altitude, one of the tourist destinations in East Java because of the potential of natural and climatic owned. Malang climate conditions during 2008 temperatures recorded ranging from 22.7 ° C to 25.1 ° C. While the maximum temperature reached 32.7 ° C and minimum temperature of 18.4 ° C. The average air humidity range 79% - 86%. With a maximum moisture content of 99% and a minimum at 40%. These conditions favor the development of the tea plant (Camellia sinensis). <br>
-
<center><img src="" width="" height=""></center>
+
<center><img src="https://static.igem.org/mediawiki/2014/e/ed/UB-Tea.PNG" width="" height=""></center><br>
Tea extract contain EGCG used as the most effective antioxidant to against cervical cancer. But, levels of EGCG (Epigallocathecin gallate) in tea is very slightly. So, we will increase the level of this EGCG compound using siRNA to knockdown gene non-EGCG with expectation it will produce high yield of antioxidant. The applications are for supplement or feminine hygiene.<br><br>
Tea extract contain EGCG used as the most effective antioxidant to against cervical cancer. But, levels of EGCG (Epigallocathecin gallate) in tea is very slightly. So, we will increase the level of this EGCG compound using siRNA to knockdown gene non-EGCG with expectation it will produce high yield of antioxidant. The applications are for supplement or feminine hygiene.<br><br>
Line 207: Line 216:
</p><br>
</p><br>
<center><img src="https://static.igem.org/mediawiki/2014/7/76/UB-AMILcp_FIX.jpg"><br>
<center><img src="https://static.igem.org/mediawiki/2014/7/76/UB-AMILcp_FIX.jpg"><br>
-
Figure 6. amilCP with his tag and C-terminus E coil
+
 
</center><br><br>
</center><br><br>
<b>D. PROTOTYPE</b><br>
<b>D. PROTOTYPE</b><br>
Line 213: Line 222:
With those concept as explained before, we’re trying to make a prototype for early detection to cervical cancer that has some common with test pack. These are our model for the prototype:
With those concept as explained before, we’re trying to make a prototype for early detection to cervical cancer that has some common with test pack. These are our model for the prototype:
</p><br>
</p><br>
-
<center><img src=""></center><br>
+
<center><img src="https://static.igem.org/mediawiki/2014/2/2c/UB-Prototype-SC.jpg"></center><br>
<p align="justify">
<p align="justify">
We test the sample from menstrual blood that we hypothesized if she got cervical cancer, the menstrual blood will go through the endometrium and then to cervix which is can bring some of the infected cells. Then the give a little bit of menstrual blood to the applicator. Inside the test pack we’ll use nitrocellulose membrane to get the result. Next steps is the binding from TALE 1 that already bind with the linker and reporter to the HPV DNA that can be found in menstrual blood. We can’t be sure if the TALE 1 and HPV DNA is binding without the TALE 2, so the sample will be catch by TALE 2 that stands for positive line. If that two TALEs can’t bind to the DNA it means negative result. Meanwhile we make control line too to compare the positive line and the control line.  
We test the sample from menstrual blood that we hypothesized if she got cervical cancer, the menstrual blood will go through the endometrium and then to cervix which is can bring some of the infected cells. Then the give a little bit of menstrual blood to the applicator. Inside the test pack we’ll use nitrocellulose membrane to get the result. Next steps is the binding from TALE 1 that already bind with the linker and reporter to the HPV DNA that can be found in menstrual blood. We can’t be sure if the TALE 1 and HPV DNA is binding without the TALE 2, so the sample will be catch by TALE 2 that stands for positive line. If that two TALEs can’t bind to the DNA it means negative result. Meanwhile we make control line too to compare the positive line and the control line.  
Line 360: Line 369:
</ul>
</ul>
<br><br>
<br><br>
-
<li>Screening</li>
+
<li><b>SCREENING</b></li>
 +
<p align="justify"><b>April – May</b><br>
 +
We found some literatures for our Screening Project and combine some projects from previous team. We decided to use Golden Gate Assembly from <a href="https://2012.igem.org/Team:Freiburg">Freiburg team 2012</a> to synthesis our TALE. Our screening kit is related to <a href="https://2013.igem.org/Team:Calgary">Calgary team 2013</a> model but we use AmylCP reporter from <a href="https://2011.igem.org/Team:Uppsala-Sweden">UPPSALA team 2011</a>. <br>
 +
<b>June-July</b><br>
 +
The TALE and AmylCP will be linked by E coil and K coil that created by  <a href="https://2013.igem.org/Team:Calgary">Calgary team 2013</a>, so we ordered them from IGEM. The bio bricks stocks is limited so we have to clone them, we transformed them to E. coli competent cell. In the beginning we use local strain E. coli but the cells has low efficiency.</p><br>
 +
<center><img src="https://static.igem.org/mediawiki/2014/9/95/UB-Lab-journal.jpg" width="500px" height="200"><br>
 +
Figure 1. <a href="http://parts.igem.org/Part:BBa_J04450">BBa_J04450</a> not inserted to local E. coli competent cell bacteria.</center><br><br>
 +
<p align="center">
 +
<b>August</b><br>
 +
We made DH5-α competent cell bacteria and test the efficiency with tansform our parts. First trial we succeded to transform our TALE direpeat parts from kit plate 2. We run the isolated plasmid into agarose gel before and after PCR.<br>
 +
</p>
 +
<center><img src="https://static.igem.org/mediawiki/2014/c/c7/UB-lab_journal2.jpg" width="500px" height="200"><br>
 +
Figure 2. The bio bricks were transformed into the new competent cell (DH5-α). Size of the parts are about 2200bp shown in the yellow box. <br><br>
 +
<img src="https://static.igem.org/mediawiki/2014/6/60/UB-lab_journal3.jpg" width="500px" height="200"><br>
 +
Figure 3. PCR products after we inserted the parts into DH5-α competent cell. The control band are shown in the K1 and K2 line that related to there is no problem with PCR technique. Only 4I part that successfully amplified.</center><br><br>
 +
<p align="justify">
 +
<b>September - October</b><br>
 +
These months we tried to synthesize our TALEs after clone the parts, but still there are 2 parts that not amplified yet (6A and 12E). We don’t have BsmBI restriction enzyme to Golden Gate Assembly but we found that EcoRI has the same restriction site as BsmBI. We substituted the BsmBI with EcoRI and  the parts successfully inserted into pSB1C3 (3200 bp).</p><br>
 +
<center><img src="https://static.igem.org/mediawiki/2014/c/c4/UB-lab_journal4.jpg" width="500px" height="200"><br>
 +
Figure 4. There are two TALES we tried to synthesize, TALE 1 and TALE 2. Every TALE has triplo but only T1-2, T2-1, and T2-2 succesfully assembled.</center><br>
 +
<p align="justify">
 +
We collected as many as possible references for the application content. Our application is android mobile based and we started to encode it. The application consist of preventing and therapy suggestion also screening method information. Special feature from our application is snap tool that can detect the kit result.
 +
</p>
</ul>
</ul>
</p>
</p>
Line 369: Line 400:
</div><!-- /col12 -->
</div><!-- /col12 -->
<div class="col-12 col-lg-4 col-sm-6">
<div class="col-12 col-lg-4 col-sm-6">
-
<a href="#"><p><i class="icon icon-glass"></i></p></a>
+
<a href="#protocols" class="fancybox"><p><i class="icon icon-tasks"></i></p></a>
 +
                                        <div id="protocols" style="display:none;width:700px;">
 +
<h2><center>“PROTOCOLS”</center></h2>
 +
<p align="justify">
 +
<b>P97 and P105 digestion. </b>
 +
<ul type="disc">
 +
<li>Add 15 ul of DNA (p97 and p105).</li>
 +
<li>Add dH20 for a total volume of 3,5 ul.</li>
 +
<li>Add 2,5ul of buffer O </li>
 +
<li>Add 0.5ul of EcoRI </li>
 +
<li>Add 0.5ul of  Xbal</li>
 +
<li>Add 0.5ul of Pstl</li>
 +
<li>There should be a total volume of 25 ul.</li>
 +
<li>Mix well and spin down.</li>
 +
<li>Incubate the restriction digest at 37˚C for 30minutes, and then 80˚C for 20minutes.</li>
 +
</ul><br>
 +
<b>SiRNADigestion</b><br>
 +
Make the composisition of the mixture, include:
 +
<ul type="circle">
 +
<li>SiRNA 2 μl (100 nmol)</li>
 +
<li>Add 10x buffer 2 μl </li>
 +
<li>Add EcoR1 1 μl (20 u/ μl)</li>
 +
<li>Add Xbal 1 μl (20 u/ μl)</li>
 +
<li>Add ddH2O 14 μl and mix gentle</li>
 +
</ul><br>
 +
 
 +
<b>PSB1C3Digestion</b><br>
 +
Make the composisition of the mixture, include:
 +
<ul type="circle">
 +
<li>ddH2O 10 μl</li>
 +
<li>Add plasmid 4 μl </li>
 +
<li>Add 10x buffer 2 μl </li>
 +
<li>Add EcoR1 2 μl</li>
 +
<li>Add Xbal 2 μl and then mix gentle</li>
 +
</ul><br>
 +
 
 +
<b>Ligation of sample and PSB1C3</b>
 +
Make the composisition of the mixture, include:
 +
<ul type="circle">
 +
<li>10x KAPA buffer 2 μl</li>
 +
<li>Add (5 u/ μl) 1 μl </li>
 +
<li>Add Psb1c3 (25 ng/ μl) 4 μl </li>
 +
<li>Add sample 4 μl</li>
 +
<li>Add ddH2O and then mix gentle</li>
 +
<li>Ligate at 16˚C for 30 minutes, then heat kill 80˚C for 20 minutes</li>
 +
<li>Transform with 2 ul of product</li>
 +
</ul><br>
 +
 
 +
<b>Transformation</b>
 +
<ul type="circle">
 +
<li>Thaw competent cells on ice.</li>
 +
<li>Place 25 µL of cells in a pre-chilled 2ml tube </li>
 +
<li>Place 25µL in 2ml tube and label it for another. Use it for control. </li>
 +
<li>Add 150 µL of resuspended DNA to 2ml tube. </li>
 +
<li>Pipet up and down gently for a few times. keep the competent cells still on ice.</li>
 +
<li>Add 1 µL of the RFP Control/li>
 +
<li>Incubate the cells on ice for30 minutes.</li>
 +
<li>Heat shock at 42ºC for 60 seconds.</li>
 +
<li>Return to ice for 5 minutes. </li>
 +
<li>Add 250 μl of SOC media to each transformation </li>
 +
<li>Incubate the cells at 37ºC for 2 hours while the tubes are rotating or shaking. Note:2 hour recovery time helps in transformation efficiency </li>
 +
<li>Do not forget to label two petri dishes with selective LB agar and kanamycin antibiotic with antibiotic resistance, part number and plasmid backbone. </li>
 +
<li>Place 20 µl and 200 µl of the transformation to dishes. Spread it. This step help ensure that you will be able to pick out a single colony.</li>
 +
<li>Place 20 µl and 200 µl of the transformation to the dishes. Spread it.</li>
 +
<li>Incubate the plates at 37ºC for 12-14 hours </li>
 +
<li>Count the colonies on the 20 μl control plate</li>
 +
<li>Calculated the competent cell.</li>
 +
</ul><br>
 +
 
 +
<b>Polymerase Chain Reaction</b><br>
 +
<ul>
 +
<li>Make the composisition of the mixture, include:</li>
 +
Add 23 μl of ddH20 <br>
 +
Add 0.5  μl of Primer Forward <br>
 +
Add 0.5 μl of Primer Reverse <br>
 +
Add 1 μl of DNA samples. There should be a volume of 25 ul <br>
 +
<li>Running on PCR machinewith 35x PCR cycle, include :</li>
 +
Hot start : 5 minutes on 94oC<br>
 +
Denaturation : 30 second on 94oC<br>
 +
Annealing : 30 second on 50oC<br>
 +
Extention : 60 second on 72oC<br>
 +
Post extention : 10 minutes on 72oC<br>
 +
</ul>
 +
 
 +
<b>Annealing Oligonucleotide</b>
 +
<ul>
 +
<li>siRNA forward (10 μl) and siRNA reverse (10 μl) mix gentle</li>
 +
<li>Add TE buffer 25 μl, ddH2O 25 μl</li>
 +
<li>Heat to 95oC for 2 minutes</li>
 +
<li>Ramp cool to 25oC over period of 45 minutes</li>
 +
</ul>
 +
 
 +
<b>Agarose Gel Electrophoresis</b><br>
 +
<ul>
 +
<li>Dissolve the 2% agar, 0,3 gr agarose on 15 ml TBE + 1 μl EtBr.</li>
 +
<li>Heat the mixture until the agar is dissolve.</li>
 +
<li>Cool the mixture and the comb on the plate.</li>
 +
<li>Pour the cooled agar in to the plate.</li>
 +
<li>When the agar has solidified, removed the come carefully.</li>
 +
<li>Places the gel in to electrophoresis chamber.</li>
 +
<li>Pour 1X TBE over gel so that gel is covered by a 3-5mm buffer.</li>
 +
<li>Load samples in the wells in the gels : 1 μl DNA and 3 μl loading dye.</li>
 +
<li>Load DNA ladder 2 μl to the well.</li>
 +
<li>Place the lid on the chamber and connect the electrode leads to the power supply.</li>
 +
<li>Turn on the power supply and adjust the voltage 50-100 volts.</li>
 +
<li>Run the gel for 5-10 minutes.</li>
 +
<li>Load samples into well.</li>
 +
<li>Hook electrodes to gel apparatus.</li>
 +
<li>Run the apparatus at 100V for 20 minutes.</li>
 +
<li>Visualize the gel and record the results by UV-transilluminator</li>
 +
</ul>
 +
 
 +
<b>Isolation Plasmid used Kit-free Alkaline Lysis Plasmid Miniprep</b><br>
 +
<ul>
 +
<li>Prepare the following solutions:</li>
 +
<pre>a. Solution I (Resuspension buffer)<br>
 +
    i. 25 mM Tris-HCl (pH 8) <br>
 +
    ii. 50 mM glucose <br>
 +
    iii. 10 mM EDTA<br><br>
 +
b. Solution II (Denaturing Solution) <br>
 +
    i. 0.2 N NaOH <br>
 +
    ii. 1.0% SDS <br><br>
 +
c. Solution III (Renaturing Solution: Potassium Acetate) <br>
 +
    i. 120 mL 5M Potassium acetate <br>
 +
    ii. 23 mL glacial acetic acid <br>
 +
    iii. 57 mL of de-ionized water<br><br>
 +
Store Solution I at 4°C <br>
 +
Store Solution II at room temperature <br>
 +
Store Solution III at 4°C<br>
 +
</pre>
 +
<li>Grow 2mL overnight cultures from single colonies of bacteria containing your plasmid of interest.</li>
 +
<li> Add 1.5mL of the stock culture to a 1.75mL microfuge tube.</li>
 +
<li>Centrifuge in microfuge tube at 10,000g for 30sec.</li>
 +
<li>Pour off the supernatant, being careful not to disturb the bacterial pellet.</li>
 +
<li>Resuspend the pellet in 100ul of cold Solution I.</li>
 +
<li>Vortex the solution for 2 minutes or until all bacteria are fully resuspended.</li>
 +
<li>Add 200μl of Solution II and invert the tube carefully 5 times to mix the contents. The contents will become clear and thicker as the proteins and DNA are denatured.</li>
 +
<li>Incubate solution on ice for 5 minutes.</li>
 +
<li>Add 150μl of cold Solution III to each tube.</li>
 +
<li>Mix by inverting several times. A white precipitate will be formed which contains the bacterial proteins and genomic DNA.</li>
 +
<li>Incubate tube on ice for 5 minutes.</li>
 +
<li>Centrifuge the tube for 5 minutes at 12,000g</li>
 +
<li>Add either 700μL of cold 100% ethanol or 350uL room temperature isopropanol to the solution to precipitate the plasmid DNA.</li>
 +
<li>Pour out the supernatant</li>
 +
<li>Air dry the pellet (can be done by inverting the tube at an angle over kimwipe) for 20-30 minutes.</li>
 +
<li>Resuspend pellet with 25-50μl of TE.</li>
 +
</ul><br><br>
 +
 
 +
<b>GATE kit For Easy TAL Effector Assembly</b>
 +
<ul><li>Choose your DNA target sequence. </li></ul>
 +
This sequence should be 14 bp long and they start and end with a thymine base.<br>
 +
1. Find the right di-repeats: <br>
 +
2. Remove the flanking thymine bases from your target sequence, split it into six pairs of nucleotides and number the repeats from one to six.To get the needed concentration of 60ng/μl please resuspend the DNA in 10μl H2O<br>
 +
</p>
 +
<center>TGCAAGTTCGAGCT<br>
 +
GC-AA-GT-TC-GA-GC<br>
 +
1. GC 2. AA 3. GT 4. TC 5. GA 6.GC<br>
 +
</center>
 +
<p align="justify">
 +
3. Insert the di-repeats into the expression vector. <br>
 +
Mix the following components in a PCR tube and  prepare a negative control lacking the di-repeats.<br>
 +
</p>
 +
<center>
 +
<table border="1">
 +
<tr><th>Component</th><th>Amount (μl)</th></tr>
 +
<tr><td>6 di-repeat plasmids (60ng)<br>
 +
Expression vector (170ng)<br>
 +
(pTALEN/pTAL-TF/pTAL-KRAB)<br>
 +
T4 Ligase Buffer (10x)<br>
 +
T4 Ligase (60 U)<br>
 +
BsmBI (15 U)<br>
 +
dH2O</td>
 +
<td>
 +
1 each<br>
 +
1<br>
 +
<br>
 +
<br>
 +
2<br>
 +
1<br>
 +
1,5<br>
 +
8,5<br>
 +
</td></tr>
 +
<tr><td>Total</td><td>20</td></tr>
 +
</table><br><br>
 +
<b>PCR Cycle</b><br>
 +
<table border="1">
 +
<tr><th>Cycle</th><th>Temperature and time</th></tr>
 +
<tr><td>1-13</td><td>37 °C, 5 minutes </td></tr>
 +
<tr><td></td><td>20 °C, 5 minutes </td></tr>
 +
<tr><td>14</td><td>50 °C, 10 minutes </td></tr>
 +
<tr><td>15</td><td>80 °C, 10 minutes </td></tr>
 +
</table>
 +
</center><br><br>
 +
4. Transform the products into a competent E. coli, such as DH10B and Top10. Note that selection of the right clones will not be successful with ccdB-resistant E.coli strains. <br>
 +
Add 5 μl of the ligation product to 50 μl of competent bacteria, incubate on ice for 30 min, perform heat shock at 42 °C for 1 minute, then incubate on ice for 5 minutes. Add 500 μl of pre-warmed LB medium, incubate at 37 °C for 1 h on a shaking thermo block, plate on an agar plate containing chlorampenicol and incubate at 37°C overnight.<br>
 +
5. Put a single colony on a new LB agar plate with chlorampenicol and Incubate for 16 hours.<br>
 +
6. If the repeat array already in the expression plasmid, then transfecting into cells.<br>
 +
7. Perform electrophoresis in order to check the successfull of TALE assembly.<br>
 +
 
 +
 
 +
 
 +
                                        </div>
<h2 class="font-thin"><font color="#fff">Protocols</font></h2>
<h2 class="font-thin"><font color="#fff">Protocols</font></h2>
<h4 class="font-thin"><font color="#fff">Detail.</font></h4>
<h4 class="font-thin"><font color="#fff">Detail.</font></h4>
Line 501: Line 733:
We upgraded the standard biobrick backbone pSB1C3 with added by promotor sequences of  p105 and GFP (E0240). This pSB1C3 has contained  chloramphenicol resistance. Our major achievements is to confirm that herbal compound can  react with promotor of HPV 16 and 18 in HeLa cells.  GFP give green colour to confirm whether herbal compound can attach and stop the HeLa cell activity transformed with p105 promotor sequence
We upgraded the standard biobrick backbone pSB1C3 with added by promotor sequences of  p105 and GFP (E0240). This pSB1C3 has contained  chloramphenicol resistance. Our major achievements is to confirm that herbal compound can  react with promotor of HPV 16 and 18 in HeLa cells.  GFP give green colour to confirm whether herbal compound can attach and stop the HeLa cell activity transformed with p105 promotor sequence
</p><br>
</p><br>
-
<center><img src="" width="" height=""></center>
+
<center><img src="https://static.igem.org/mediawiki/2014/f/f9/UB-BBa_E0240_-_P105_Map.png" width="500px" height="400"></center>
<p align="justify">
<p align="justify">
Line 507: Line 739:
Standard biobrick backbone pSB1C3 containing chloramphenicol resistance.  The backbone added  by promotor sequences of  p97 and GFP (E0240).  GFP act as a marker that give green colour to confirm  whether herbal compound can attach  and stop the HeLa cell activity transformed with p97 promotor sequence.
Standard biobrick backbone pSB1C3 containing chloramphenicol resistance.  The backbone added  by promotor sequences of  p97 and GFP (E0240).  GFP act as a marker that give green colour to confirm  whether herbal compound can attach  and stop the HeLa cell activity transformed with p97 promotor sequence.
</p><br>
</p><br>
-
<center><img src="" width="" height=""></center>
+
<center><img src="https://static.igem.org/mediawiki/2014/1/15/UB-BBa_EO240_-_p97_Map.png" width="500px" height="400"></center>
 +
<br><br>
 +
<b>Preventing and Therapy Team Safety</b>
 +
<center><table border="1">
 +
<tr><th>Part Number</th><th>DNA Source</th><th>Species Origin</th><th>Species Risk Group</th><th>Part Function</th></tr>
 +
<tr><td>Bba_K747096</td><td>Part registry</td><td>E. coli DH5α</td><td>1</td><td>CMV Promoter</td></tr>
 +
<tr><td>Bba_E0240</td><td>Part registry</td><td>E. coli DH5α</td><td>1</td><td>GFP Generator</td></tr>
 +
<tr><td>Bba_K516132</td><td>Part registry</td><td>E. coli DH5α</td><td>1</td><td>Constitutive promoter with mRFP, RBS B0032</td></tr>
 +
<tr><td>pTALEN</td><td>From BIOSS in University of Freiburg, Germany</td><td>Xanthomonas spp.</td><td>2</td><td>Vector</td></tr>
 +
<tr><td>pTAL-TF</td><td>From BIOSS in University of Freiburg, Germany</td><td>Xanthomonas spp.</td><td>2</td><td>Vector</td></tr>
 +
<tr><td>p97 promoter</td><td>Synthesized by IDT</td><td>HPV type 16</td><td>2</td><td>Cell Line</td></tr>
 +
<tr><td>p105 promoter</td><td>Synthesized by IDT</td><td>HPV type 16</td><td>2</td><td>Cell Line</td></tr>
 +
</table>
 +
<br><br>
 +
<table border="1">
 +
<tr><th>Part Number</th><th>DNA Source</th><th>Species Origin</th><th>Species Risk Group</th><th>Part Function</th></tr>
 +
<tr><td>Bba_K747012</td><td>Part registry</td><td>E. coli DH5α</td><td>1</td><td>Protein Domain </td></tr>
 +
<tr><td>Bba_K747016</td><td>Part registry</td><td>E. coli DH5α</td><td>1</td><td>Protein Domain </td></tr>
 +
<tr><td>Bba_K747042</td><td>Part registry</td><td>E. coli DH5α</td><td>1</td><td>Protein Domain </td></tr>
 +
<tr><td>Bba_K747048</td><td>Part registry</td><td>E. coli DH5α</td><td>1</td><td>Protein Domain </td></tr>
 +
<tr><td>Bba_K747064</td><td>Part registry</td><td>E. coli DH5α</td><td>1</td><td>Protein Domain </td></tr>
 +
<tr><td>Bba_K747091</td><td>Part registry</td><td>E. coli DH5α</td><td>1</td><td>Protein Domain </td></tr>
 +
<tr><td>Bba_K747012</td><td>Part registry</td><td>E. coli DH5α</td><td>1</td><td>Protein Domain </td></tr>
 +
<tr><td>Bba_K747026</td><td>Part registry</td><td>E. coli DH5α</td><td>1</td><td>Protein Domain </td></tr>
 +
<tr><td>Bba_K747036</td><td>Part registry</td><td>E. coli DH5α</td><td>1</td><td>Protein Domain </td></tr>
 +
<tr><td>Bba_K747052</td><td>Part registry</td><td>E. coli DH5α</td><td>1</td><td>Protein Domain </td></tr>
 +
<tr><td>Bba_K747076</td><td>Part registry</td><td>E. coli DH5α</td><td>1</td><td>Protein Domain </td></tr>
 +
<tr><td>Bba_K747095</td><td>Part registry</td><td>E. coli DH5α</td><td>1</td><td>Protein Domain </td></tr>
 +
<tr><td>Bba_K747101</td><td>Part registry</td><td>E. coli DH5α</td><td>1</td><td>Plasmid </td></tr>
 +
 
 +
</table>
 +
</center>
                                         </div>
                                         </div>
<h2 class="font-thin"><font color="#fff">Submitted Parts</font></h2>
<h2 class="font-thin"><font color="#fff">Submitted Parts</font></h2>
Line 540: Line 803:
<div class="col-12 col-sm-6 col-lg-2"><a data-fancybox-group="portfolio" class="fancybox" href="https://static.igem.org/mediawiki/2014/4/4d/UB-Advisor.JPG"><img class="thumb" src="https://static.igem.org/mediawiki/2014/4/4d/UB-Advisor.JPG" alt=""></a></div>
<div class="col-12 col-sm-6 col-lg-2"><a data-fancybox-group="portfolio" class="fancybox" href="https://static.igem.org/mediawiki/2014/4/4d/UB-Advisor.JPG"><img class="thumb" src="https://static.igem.org/mediawiki/2014/4/4d/UB-Advisor.JPG" alt=""></a></div>
<div class="col-12 col-sm-6 col-lg-2"><a data-fancybox-group="portfolio" class="fancybox" href="https://static.igem.org/mediawiki/2014/0/03/Foto_seminar_biologi_sintetikUB.jpg"><img class="thumb" src="https://static.igem.org/mediawiki/2014/0/03/Foto_seminar_biologi_sintetikUB.jpg" alt=""></a></div>
<div class="col-12 col-sm-6 col-lg-2"><a data-fancybox-group="portfolio" class="fancybox" href="https://static.igem.org/mediawiki/2014/0/03/Foto_seminar_biologi_sintetikUB.jpg"><img class="thumb" src="https://static.igem.org/mediawiki/2014/0/03/Foto_seminar_biologi_sintetikUB.jpg" alt=""></a></div>
-
<div class="col-12 col-sm-6 col-lg-2"><a data-fancybox-group="portfolio" class="fancybox" href="images/portfolio/p03-large.jpg"><img class="thumb" src="https://static.igem.org/mediawiki/2014/4/4b/Wiraeka.jpg" alt=""></a></div>
+
<div class="col-12 col-sm-6 col-lg-2"><a data-fancybox-group="portfolio" class="fancybox" href="https://static.igem.org/mediawiki/2014/c/c0/UB-labwork4.JPG"><img class="thumb" src="https://static.igem.org/mediawiki/2014/c/c0/UB-labwork4.JPG" alt=""></a></div>
-
<div class="col-12 col-sm-6 col-lg-2"><a data-fancybox-group="portfolio" class="fancybox" href="images/portfolio/p04-large.jpg"><img class="thumb" src="https://static.igem.org/mediawiki/2014/4/4b/Wiraeka.jpg" alt=""></a></div>
+
<div class="col-12 col-sm-6 col-lg-2"><a data-fancybox-group="portfolio" class="fancybox" href="https://static.igem.org/mediawiki/2014/e/e0/UB-labwork1.JPG"><img class="thumb" src="https://static.igem.org/mediawiki/2014/e/e0/UB-labwork1.JPG" alt=""></a></div>
-
<div class="col-12 col-sm-6 col-lg-2"><a data-fancybox-group="portfolio" class="fancybox" href="images/portfolio/p11-large.jpg"><img class="thumb" src="https://static.igem.org/mediawiki/2014/4/4b/Wiraeka.jpg" alt=""></a></div>
+
<div class="col-12 col-sm-6 col-lg-2"><a data-fancybox-group="portfolio" class="fancybox" href="https://static.igem.org/mediawiki/2014/b/b0/UB-labwork2.JPG"><img class="thumb" src="https://static.igem.org/mediawiki/2014/b/b0/UB-labwork2.JPG" alt=""></a></div>
-
<div class="col-12 col-sm-6 col-lg-2"><a data-fancybox-group="portfolio" class="fancybox" href="images/portfolio/p12-large.jpg"><img class="thumb" src="https://static.igem.org/mediawiki/2014/4/4b/Wiraeka.jpg" alt=""></a></div>
+
<div class="col-12 col-sm-6 col-lg-2"><a data-fancybox-group="portfolio" class="fancybox" href="https://static.igem.org/mediawiki/2014/e/e4/UB_Go_Get_GOLD.jpg"><img class="thumb" src="https://static.igem.org/mediawiki/2014/e/e4/UB_Go_Get_GOLD.jpg" alt=""></a></div>
</div><!-- /row -->
</div><!-- /row -->
</div><!-- /slide3 -->
</div><!-- /slide3 -->
Line 563: Line 826:
<div class="row content-row">
<div class="row content-row">
<div class="col-12 col-lg-4 col-sm-6">
<div class="col-12 col-lg-4 col-sm-6">
-
<a class="open_fancybox" href="https://static.igem.org/mediawiki/2014/a/ad/Ub28.JPG"><p><i class="icon icon-user"></i></p></a>
+
<a class="open_fancybox" href="https://static.igem.org/mediawiki/2014/f/fc/Karikatur_Pak_Wid.jpg"><p><i class="icon icon-user"></i></p></a>
<script type="text/javascript">
<script type="text/javascript">
$(".open_fancybox").click(function() {
$(".open_fancybox").click(function() {
Line 569: Line 832:
     $.fancybox.open([
     $.fancybox.open([
         {
         {
-
             href : 'https://static.igem.org/mediawiki/2014/4/4b/Wiraeka.jpg',                 
+
             href : 'https://static.igem.org/mediawiki/2014/f/fc/Karikatur_Pak_Wid.jpg',                 
-
             title : 'Imunology',
+
             title : 'Widodo, S.Si., M.Si., Ph.D.Med.Sc (SUPERVISOR)',
              
              
         },
         },
         {
         {
-
             href : 'https://static.igem.org/mediawiki/2014/9/9f/Ub17.JPG',                 
+
             href : 'https://static.igem.org/mediawiki/2014/2/20/UB-Candra_dewi.jpg',                 
-
             title : '2nd title'
+
             title : 'Candra Dewi, S.Kom, M.Sc (IT ADVISOR)'
         },
         },
         {
         {
-
             href : 'https://static.igem.org/mediawiki/2014/5/5b/Ub23.JPG',                 
+
            href : 'https://static.igem.org/mediawiki/2014/5/51/UB-Laras.PNG',               
-
             title : '3rd title'
+
            title : 'Prof.Dr.Ir. Estri Laras Arumningtyas, M.Sc.St (MOLECULAR BIOLOGY ADVISOR)'
 +
        },
 +
        {
 +
            href : 'https://static.igem.org/mediawiki/2014/d/dd/UB-GALUH.JPG',               
 +
            title : 'Galuh Wening(Preventing Team Member)'
 +
           
 +
        },
 +
        {
 +
            href : 'https://static.igem.org/mediawiki/2014/6/6b/UB-FERLANY.jpg',               
 +
            title : 'Ferlany Hardiyanti (Preventing Team Member)'
 +
        },
 +
        {
 +
             href : 'https://static.igem.org/mediawiki/2014/5/5b/UB-AZZA.JPG',                 
 +
             title : 'Azza Hanif Harisna (Preventing Team Member)'
 +
        },
 +
        {
 +
            href : 'https://static.igem.org/mediawiki/2014/2/2e/UB-IGA.jpg',               
 +
            title : 'Iga Dwi Januarisasi (Preventing Team Member)'
 +
           
 +
        },
 +
        {
 +
            href : 'https://static.igem.org/mediawiki/2014/3/33/UB-ISNA.jpg',               
 +
            title : 'Isna Arofatun (Preventing Team Member)'
 +
        },
 +
        {
 +
            href : 'https://static.igem.org/mediawiki/2014/a/ac/UB-Ana.jpg',               
 +
            title : 'Roudlutul Jannah (Screening Team Member)'
 +
           
 +
        },
 +
        {
 +
            href : 'https://static.igem.org/mediawiki/2014/4/4b/UB-Agatha_cantik.jpg',               
 +
            title : 'Agatha Mia (Screening Team Member)'
 +
        },
 +
        {
 +
            href : 'https://static.igem.org/mediawiki/2014/3/39/UB-Mak_her.jpg',               
 +
            title : 'Herlinda Mawardika (Screening Team Member)'
 +
        },
 +
        {
 +
            href : 'https://static.igem.org/mediawiki/2014/8/8a/UB-Arfan.PNG',               
 +
            title : 'Arfan Tri Kusuma R F (Screening Team Member)'
 +
           
 +
        },
 +
        {
 +
            href : 'https://static.igem.org/mediawiki/2014/6/67/UB-Mas_wasis.jpg',               
 +
            title : 'Wasis Poernomo (Screening Team Member)'
 +
           
 +
        },
 +
        {
 +
            href : 'https://static.igem.org/mediawiki/2014/4/41/UB-Mas_fahad.jpg',               
 +
            title : 'Fahad Arwani (Screening Team Member)'
 +
        },
 +
        {
 +
            href : 'https://static.igem.org/mediawiki/2014/0/0d/UB-Ami.jpg',               
 +
            title : 'Aisyah Ami Wardhani (Screening Team Member)'
 +
           
 +
        },
 +
        {
 +
            href : 'https://static.igem.org/mediawiki/2014/5/5f/UB-Wisnu_wijaya.PNG',               
 +
            title : 'Wisnu Wijaya (Screening Team Member)'
 +
        },
 +
        {
 +
            href : 'https://static.igem.org/mediawiki/2014/2/24/UB-Firda.PNG',               
 +
            title : 'Firda Agustin (Therapy Team Member)'
 +
           
 +
        },
 +
        {
 +
            href : 'https://static.igem.org/mediawiki/2014/5/5b/UB-Yola.PNG',               
 +
            title : 'Yolanda Antonius (Therapy Team Member)'
 +
        },
 +
        {
 +
            href : 'https://static.igem.org/mediawiki/2014/d/d4/UB-wira.PNG',               
 +
            title : 'Wira Eka Putra (Therapy Team Member)'
 +
        },
 +
        {
 +
            href : 'https://static.igem.org/mediawiki/2014/9/9f/UB-Nira.PNG',               
 +
            title : 'Nira Meirita Wijayanti (Therapy Team Member)'
 +
           
 +
        },
 +
        {
 +
            href : 'https://static.igem.org/mediawiki/2014/7/70/UB-Maul.jpg',               
 +
            title : 'Maulana Malik Nashrullah (Therapy Team Member)'
         }
         }
     ], {
     ], {
Line 595: Line 938:
</div><!-- /col12 -->
</div><!-- /col12 -->
<div class="col-12 col-lg-4 col-sm-6">
<div class="col-12 col-lg-4 col-sm-6">
-
<a href="#"><p><i class="icon icon-star"></i></p></a>
+
<a href="#sponsor" class="fancybox"><p><i class="icon icon-star"></i></p></a>
 +
                                        <div id="sponsor" style="display:none;width:700px;">
 +
                                        <center><img src="https://static.igem.org/mediawiki/2014/d/d6/UB-Sponsors.jpg" width="500" height="400"></center>
 +
                                        </div>
<h2 class="font-thin"><font color="#fff">Sponsors</font></h2>
<h2 class="font-thin"><font color="#fff">Sponsors</font></h2>
</div><!-- /col12 -->
</div><!-- /col12 -->

Latest revision as of 19:18, 16 October 2014

iGEM2014 | UB INDONESIA

BRAWIJAYA UNIVERSITY , INDONESIA

This is team wiki to share our iGEM experience



iGEM UB
BRAWIJAYA UNIVERSITY
iGEM2014
PROJECT
 
Abstract ...

Background

Overview

Preventing

Screening

Therapy

NOTEBOOK
 
Description

Timeline

Lab Journal

Detail.

Protocols

Detail.

HUMAN PRACTICE
 
Teks description

Workshop

Education

Society

COLLABORATIONS
 
Description

SYNBIO FOR INDONESIA

PARTS
 
Description

Submitted Parts

Favorite Parts

ABOUT US
 
Description

Members

Sponsors

Leave us a message
 
You can find us literally anywhere,

just push a button and we’re there

in/igemub

igemub@gmail.com

Malang, Indonesia
zip code 65145

facebook/igembrawijaya

@igem_ub